Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GB SciencesGBLX Scaled Net Operating Assets is -41.37 as of Dec. 2024.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
GB Sciences's operating assets for the quarter that ended in Dec. 2024 was $0.09 Mil. GB Sciences's operating liabilities for the quarter that ended in Dec. 2024 was $3.98 Mil. GB Sciences's Total Assets for the quarter that ended in Sep. 2024 was $0.09 Mil. Therefore, GB Sciences's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was -41.37.
GB Sciences Scaled Net Operating Assets Related Terms
GB Sciences Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for GB Sciences's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GBLX vs QRON, ENDV, CNBX: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, GB Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GB Sciences Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GB Sciences's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where GB Sciences's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -41.37 mean?
GB Sciences (GBLX) has a Scaled Net Operating Assets of -41.37 as of Dec. 2024. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on GB Sciences and its competitors.
Is GB Sciences' Scaled Net Operating Assets too high?
GB Sciences' current Scaled Net Operating Assets is -41.37.
How does GB Sciences' Scaled Net Operating Assets compare to QRON and ENDV?
GB Sciences' Scaled Net Operating Assets of -41.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on GB Sciences and its competitors. GB Sciences's current Scaled Net Operating Assets is -41.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GB Sciences stock overvalued right now?
GB Sciences (GBLX) has a current Scaled Net Operating Assets of -41.37. The current Scaled Net Operating Assets is -41.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For GB Sciences (GBLX), the current Scaled Net Operating Assets is -41.37 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GBLX has been successfully added to your 
